Observational case-control study (n=60; 30 TRD, 30 healthy controls) assessing EEG and behavioural measures 24 hours after a subanesthetic ketamine injection given as part of clinical care.
This observational case-control study recruits 30 individuals with treatment-resistant major depressive disorder who are already scheduled to receive clinical ketamine treatment and 30 demographically matched healthy controls. Primary assessments include resting-state EEG, cognitive-control tasks, and reward-learning measures performed 24 hours after ketamine administration.
Participants undergo questionnaires, urine drug screening, and electrophysiological recording (EEG); eligibility is confirmed via structured clinical interview and depression scales (IDS-C30, QIDS, HDRS). Healthy controls must have no psychiatric history and no first-degree relative with mood or psychotic disorder.
Participants with current major depressive disorder receiving ketamine as part of standard clinical care.
Single subanesthetic ketamine infusion administered as part of clinical care; EEG and assessments at 24 hours post-injection.
Demographically matched healthy control subjects with no history of clinical depression or other psychiatric disorder.